Cart
sales@molnova.com
Pimicotinib
CAS No. 2253123-16-7
Pimicotinib( —— )
Catalog No. M37228 CAS No. 2253123-16-7
Pimicotinib (ABSK021) is a potent CSF1R inhibitor with antitumor activity and can be used to study advanced solid tumors.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 1 mL x 10 mM in DMSO | 150 | In Stock |
|
| 5MG | 107 | In Stock |
|
| 10MG | 170 | In Stock |
|
| 25MG | 330 | In Stock |
|
| 50MG | 517 | In Stock |
|
| 100MG | 826 | In Stock |
|
| 200MG | Get Quote | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NamePimicotinib
-
NoteResearch use only, not for human use.
-
Brief DescriptionPimicotinib (ABSK021) is a potent CSF1R inhibitor with antitumor activity and can be used to study advanced solid tumors.
-
DescriptionPimicotinib is a CSF1R inhibitor with antitumor activity.
-
In Vitro——
-
In Vivo——
-
Synonyms——
-
PathwayTyrosine Kinase
-
TargetCSF1R
-
Recptorc-Fms
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number2253123-16-7
-
Formula Weight420.46
-
Molecular FormulaC22H24N6O3
-
Purity>98% (HPLC)
-
SolubilityIn Vitro:?DMSO : 100 mg/mL (237.83 mM; Ultrasonic )
-
SMILESO=C(NC=1N=C(C(OC2=CC=NC(=C2)C=3C=NN(C3)C)=CC1)C)N4C(=O)C(C)(C)CC4
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Zhao BW, et al. N-(azaaryl)cyclolactam-1-carboxamide derivative, preparation method and application. World Intellectual Property Organization, WO2018214867 A1. 2018-11-29.
molnova catalog
related products
-
Emactuzumab
Emactuzumab(RG 7155) is a monoclonal antibody against colony-stimulating factor-1 receptor targeting tumor-associated macrophages (TAMs) Emactuzumab has antitumor activity and inhibits activation of colony-stimulating factor 1 receptor (CSF1R) Emactuzumab has a high affinity for CSF-1R with a Ki value of 0.2 nM.
-
c-Fms-IN-1
c-Fms-IN-1 is an inhibitor of c-FMS kinase (IC50 = 0.8 nM).
-
Vimseltinib
DCC-3014 is a c-FMS (CSF-IR) and c-Kit dual inhibitor (IC50s: <0.01 μM and 0.1-1 μM) extracted from the patent WO2014145025A2 (Example 10).
